Orlov S. Nicole Schaeffer - Nov 1, 2021 Form 4 Insider Report for INSMED Inc (INSM)

Role
Chief People Strategy Officer
Signature
/s/ S. Nicole Schaeffer
Stock symbol
INSM
Transactions as of
Nov 1, 2021
Transactions value $
-$1,088,512
Form type
4
Date filed
11/3/2021, 04:27 PM
Previous filing
May 18, 2021
Next filing
Jan 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INSM Common Stock Options Exercise $759K +61K +118.41% $12.44 113K Nov 1, 2021 Direct F1, F2
transaction INSM Common Stock Sale -$1.84M -60.7K -53.91% $30.28 51.9K Nov 1, 2021 Direct F1, F3
transaction INSM Common Stock Sale -$10.6K -340 -0.66% $31.08 51.5K Nov 1, 2021 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INSM Stock Option (right to buy) Options Exercise $0 -36K -59.02% $0.00 25K Nov 1, 2021 Common Stock 36K $12.44 Direct F5
transaction INSM Stock Option (right to buy) Options Exercise $0 -25K -100% $0.00* 0 Nov 1, 2021 Common Stock 25K $12.44 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 Includes 722 shares acquired through the Company's 2018 Employee Stock Purchase Plan.
F3 This is the weighted average sales price representing 60,660 shares sold at prices ranging from $30.00 to $30.99 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F4 This is the weighted average sales price representing 340 shares sold at prices ranging from $31.00 to $31.14 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F5 The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
F6 These options vested and became exercisable with respect to 12,500 shares upon receipt of the first written acceptance of an NDA or MAA filing from an applicable regulatory authority (FDA or EMA); and with respect to the remaining 12,500 shares upon receipt of the first written approval of an NDA or MAA filing from an applicable regulatory authority (FDA or EMA).